Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
doi:10.1093/eurheartj/ehi044
ESC Guidelines
Document Reviewers, Maria Angeles Alonso Garcia (Co-CPG Review Coordinator) (Spain),
Kenneth Dickstein (Co-CPG Review Coordinator) (Norway), Anibal Albuquerque (Portugal), Pedro Conthe (Spain),
Maria Crespo-Leiro (Spain), Roberto Ferrari (Italy), Ferenc Follath (Switzerland), Antonello Gavazzi (Italy),
Uwe Janssens (Germany), Michel Komajda (France), Joao Morais (Portugal), Rui Moreno (Portugal),
Mervyn Singer (UK), Satish Singh (UK), Michal Tendera (Poland), Kristian Thygesen (Denmark)
& The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
ESC Guidelines 385
II. Treatment of AHF . . . . . . . . . . . . . . . . . . 394 well dened, recent surveys of Guidelines and Expert
8. General medical issues in the Consensus Documents published in peer-reviewed jour-
treatment of AHF . . . . . . . . . . . . . . . . 394 nals between 1985 and 1998 have shown that methodo-
9. Oxygen and ventilatory assistance . . . . . . 395 logical standards were not complied with in the vast
9.1. Rationale for using oxygen in AHF . . . . 395 majority of cases. It is therefore of great importance
9.2. Ventilatory support without that guidelines and recommendations are presented
endotracheal intubation (non-invasive in formats that are easily interpreted. Subsequently,
ventilation) . . . . . . . . . . . . . . . . . 395 their implementation programmes must also be well
9.3. Mechanical ventilation with conducted. Attempts have been made to determine
endotracheal intubation in AHF . . . . . 396 whether guidelines improve the quality of clinical prac-
10. Medical treatment . . . . . . . . . . . . . . . 396 tice and the utilization of health resources.
10.1. Morphine and its analogues in AHF . . 396 The ESC Committee for Practice Guidelines (CPG)
10.2. Anticoagulation . . . . . . . . . . . . . 396 supervises and coordinates the preparation of new Guide-
10.3. Vasodilators in the treatment of AHF 396 lines and Expert Consensus Documents produced by Task
10.4. Angiotensin converting enzyme Forces, expert groups or consensus panels. The chosen
(ACE)-inhibitors in AHF . . . . . . . . . 397 experts in these writing panels are asked to provide dis-
10.5. Diuretics . . . . . . . . . . . . . . . . . 398 closure statements of all relationships they may have
10.6. b-blocking agents . . . . . . . . . . . . 399 which might be perceived as real or potential conicts
10.7. Inotropic agents . . . . . . . . . . . . . 400 of interest. These disclosure forms are kept on le at
hypoperfusion
panied by severe respiratory distress, with crackles
, with CNS
symptoms
End organ over the lung and orthopnoea, with O2 saturation
usually ,90% on room air prior to treatment.
/ 2
2 (iv) Cardiogenic shock: Cardiogenic shock is dened as
evidence of tissue hypoperfusion induced by heart
failure after correction of pre-load. There is no
clear denition for haemodynamic parameters,
Hypoperfusion
acute onset
which explains the differences in prevalence and
outcome reported in studies (Table 2 ), but cardio-
genic shock is usually characterized by reduced
/2,
/ 2
/ 2
/ 2
blood pressure (systolic BP ,90 mmHg or a drop of
2
mean arterial pressure . 30 mmHg) and/or low
urine output (,0.5 ml/kg/h), with a pulse rate
.60 b.p.m. with or without evidence of organ con-
Very low
Diuresis
/ 2
low
The differentation from low cardiac output syndrome is subjective and the clinical presentation may overlap these classications.
K IV/F IV
KIII/FII
/ 2
.18
.16
.18
Mild
Low
/ 2
,1.8
Low
CI
Low normal
Low normal
/ 2
High
,90
Low
decompensation;
Stage IIHeart failure. Diagnostic criteria include rales,
S3 gallop and pulmonary venous hypertension.
increased
Usually low
Heart rate
.90
diaphoresis.
V High output failure
VI Right sided acute
shock
hypotension, tachycardia, confusion, oliguria) and pul- pulmonary emboli, (ii) increased pre-load due to
monary congestion (rales, abnormal chest X-ray), and increased volume intake or reduced excretion due to
haemodynamically on the basis of a depressed cardiac renal failure or endocrinopathy, or (iii) high output
index (2.2 L/min/m2) and elevated pulmonary capillary state due to infection, thyrotoxicosis, anaemia, Pagets
pressure (.18 mmHg). The original paper dened the disease. Heart failure can be complicated by co-existing
treatment strategy according to the clinical and haemo- end-organ disease. Severe heart failure can also induce
dynamic status. Mortality was 2.2% in group I, 10.1% in multi-organ failure, which may be lethal.
group II, 22.4% in group III, and 55.5% in group IV. Appropriate long-term medical therapy and, if pos-
sible, anatomical correction of the underlying patho-
3.1.3. Clinical severity classication. The clinical
logy may prevent further AHF syndrome attacks and
severity classication is based on observation of the
improve the poor long-term prognosis associated with
peripheral circulation (perfusion) and on auscultation of
this syndrome.
the lungs (congestion). The patients can be classied as
The clinical AHF syndrome may be classied as predo-
Class I (Group A) (warm and dry), Class II (Group B)
minantly left or right forward failure, left or right back-
(warm and wet), Class III (Group L) (cold and dry), and
ward failure, or a combination of these.
Class IV (Group C) (cold and wet). This classication has
been validated prognostically in a cardiomyopathy
service,20 and is therefore applicable to patients
3.2.1. Forward (left and right) AHF. Forward acute
with chronic heart failure, whether hospitalized or
heart failure may be mild-to-moderate with only effort
outpatients.
fatigue, up to severe with manifestations of reduced
3.2. The clinical syndrome of AHF tissue perfusion at rest with weakness, confusion, drowsi-
AHF is a clinical syndrome, with reduced cardiac output, ness, paleness with peripheral cyanosis, cold clammy
tissue hypoperfusion, increase in the pulmonary capillary skin, low blood pressure, lliform pulse, and oliguria, cul-
wedge pressure (PCWP), and tissue congestion. The minating in the full blown presentation of cardiogenic
underlying mechanism may be cardiac or extra-cardiac, shock.
and may be transient and reversible with resolution of This syndrome may be induced by a large variety of
the acute syndrome, or may induce permanent damage pathologies. An adequate history may indicate the main
leading to chronic heart failure. The cardiac dysfunc- diagnosis for example (i) acute coronary syndrome with
tion can be related to systolic or diastolic myocardial the relevant risk factors, past history, and suggestive
dysfunction (mainly induced by ischaemia or infection), symptoms; (ii) acute myocarditis with a recent history
acute valvular dysfunction, pericardial tamponade, suggestive of acute viral infection; (iii) acute valvular
abnormalities of cardiac rhythm, or pre-load/after-load dysfunction with a history of chronic valve disease or
mismatch. Multiple extra-cardiac pathologies may result valve surgery, infection with the possibility of bacterial
in acute heart failure by changing the cardiac loading endocarditis, or chest trauma; (iv) pulmonary embolism
conditions for example (i) increased after-load due with a relevant history and suggestive symptoms; or
to systemic or pulmonary hypertension or massive (v) pericardial tamponade.
ESC Guidelines 389
Physical examination of the cardiovascular system may The typical presentation is with fatigue, pitting ankle
be indicative of the main diagnosis, for example by dis- oedema, tenderness in the upper abdomen (due to liver
tended neck veins and paradoxical pulse (pericardial congestion), shortness of breath (with pleural effusion)
tamponade), mufed heart sounds related to myocardial and distension of the abdomen (with ascites). The
systolic dysfunction, or the disappearance of articial full-blown syndrome includes anasarca with liver dysfunc-
valve sounds or an appropriate murmur indicating a valv- tion and oliguria.
ular problem. History and physical examination should conrm the
In forward AHF immediate management should include syndrome of acute right heart failure, indicate the sus-
supportive treatment to improve cardiac output and pected diagnosis and guide further investigation, which
tissue oxygenation. This can be achieved with vasodilat- is likely to include ECG, blood gases, D-dimer, chest
ing agents, uid replacement to achieve an optimal X-ray, cardiac Doppler-echocardiography, angiography
pre-load, short-term inotropic support and (sometimes) or chest CT scan.
intra-aortic balloon counterpulsation. In right heart backward failure uid overload is
managed with diuretics, including spironolactone, and
sometimes with a short course of low dose (diuretic
3.2.2. Left-heart backward failure. Left-heart back-
dose) of dopamine. Concomitant treatment may
ward failure may be related to left ventricular
include: antibiotics for pulmonary infection and bacterial
dysfunction with varying degrees of severity, from mild-
endocarditis; Ca channel blockers, nitric oxide, or
to-moderate with only exertional dyspnoea, to pulmonary
prostaglandins for primary pulmonary hypertension; and
oedema presenting with shortness of breath (dry cough,
Left sided lling pressure is assessed by chest ausculta- cardiac conditions (cardiac size and shape) and to assess
tion, with the presence of wet rales in the lung elds pulmonary congestion. It is used both for conrmation of
usually indicating raised pressure. The conrmation, the diagnosis, and for follow-up of improvement or unsa-
classication of severity, and clinical follow-up of pul- tisfactory response to therapy. Chest X-ray allows the
monary congestion and pleural effusions should be done differential diagnosis of left heart failure from inamma-
using the chest X-ray. tory or infectious lung diseases. Chest CT scan with or
Class I recommendation, level of evidence C without contrast angiography and scintigraphy may be
used to clarify the pulmonary pathology and diagnose
Again, in acute conditions the clinical evaluation of major pulmonary embolism. CT scan or transesophageal
left-sided lling pressure may be misleading due to the echocardiography should be used in cases of suspicion
rapidly evolving clinical situation. Cardiac palpation and of aortic dissection.
auscultation for ventricular and atrial gallop rhythms
(S3, S4) should be performed. The quality of the heart 5.4. Laboratory tests
sounds, and the presence of atrial and ventricular A number of laboratory tests should be performed in AHF
gallops and valvular murmurs are important for diagnosis patients (Table 3 ). Arterial blood gas analysis (Astrup)
and clinical assessment. Assessment of the extent of enables assessment of oxygenation (pO2), respiratory
arteriosclerosis by detecting missing pulses and the pre- adequacy (pCO2), acidbase balance (pH), and base
sence of carotid and abdominal bruits is often important, decit, and should be performed in all patients with
particularly in elderly subjects. severe heart failure. Non-invasive measurement with
Figure 5 Immediate goals in treatment of the patients with AHF. In coronary patients mean blood pressure (mBP) should be higher to ensure coronary
perfusion, mBP .70, or systolic .90 mmHg.
ESC Guidelines 393
in congestive and oliguric patients with AHF.44,53 Simi- 7.1. Non-invasive monitoring
larly, an improvement in oxygen saturation, renal and/ In all critically ill patients, BP measurements should
or hepatic function, and/or serum electrolytes are mean- be made routinely; blood pressure, temperature,
ingful goals of treatment. Plasma BNP concentration can respiratory rate, heart rate, the electrocardiogram and
reect haemodynamic improvement and decreased blood pressure is mandatory. Some laboratory tests
levels are benecial. should be done repeatedly i.e. electrolytes, creatinine
Benecial effects of therapy on outcome include and glucose or markers for infection or other metabolic
reductions in the duration of intravenous vasoactive disorders. Hypo or hyperkalaemia must be controlled.
therapy, the length of stay, and the readmission These can all be monitored easily and accurately with
rate with an increase in the time to readmission.52,54,55 modern automated equipment. If the patient becomes
A reduction in both in-hospital and long-term mortality more unwell, the frequency of these observations will
is also a major goal of treatment. need to be increased.
Lastly, a favourable safety and tolerability prole is ECG monitoring (arrhythmias and ST segment) is
also necessary for any treatment used in patients with necessary during the acute decompensation phase, par-
AHF. Any agent used in this condition should be associ- ticularly if ischaemia or arrhythmia is responsible for
ated with a low withdrawal rate with a relatively low the acute event.
incidence of untoward side effects. Class I recommendation, level of evidence C
and are therefore useful for the delivery of uids and Several retrospective studies assessing the use of the
drugs and can also be used to monitor the CVP and PAC in acute myocardial infarction demonstrated
venous oxygen saturation (SvO2) in the superior vena increased mortality with the PAC. These observations
cava (SVC) or right atrium, which provides an estimate were partially explained by case-mix differences
of oxygen transport. between the groups of the study.5961 Similar observa-
Class II b recommendation, level of evidence C tional ndings have subsequently been reported in
other groups of patients.47,61,62 A recent prospective
Caution has to be advised, however, to avoid the randomized study enrolling a mixed group of critically ill
over-interpretation of right atrial pressure measure- patients failed to demonstrate a difference in outcome,
ments, as these rarely correlate with left atrial pres- although randomization to the PAC led to increased
sures, and therefore left ventricular (LV) lling uid resuscitation within the rst 24 h. The PAC did not
pressures, in patients with AHF. CVP measurements are cause harm to patients, rather it was the use of the infor-
also affected by the presence of signicant tricuspid mation derived from the catheter (sometimes in an inap-
regurgitation and positive end-expiratory pressure propriate fashion) that was detrimental.48
(PEEP) ventilation. The use of a PAC is recommended in haemodynamically
Class I recommendation, level of evidence C unstable patients who are not responding in a predictable
fashion to traditional treatments, and in patients with
a combination of congestion and hypoperfusion. In
7.2.3. Pulmonary artery catheter. The pulmonary these cases it is inserted in order to ensure optimal
In AHF patients: Decreased CI: ,2.2 L/min/m2; PCWP: low if ,14 mmHg, high if .1820 mmHg.
ESC Guidelines 395
urinary tract infections, septicaemia, or nosocomial 9.2. Ventilatory support without endotracheal
infection with Gram positive bacteria. An increase in intubation (non-invasive ventilation)
C-reactive protein (CRP) and a decrease in general con- Two techniques are used for ventilatory support:
dition may be the only signs of infectionfever may be CPAP or non-invasive positive pressure ventilation
absent. Meticulous infection control and measures to (NIPPV). NIPPV is a method of providing mechanical
maintain skin integrity are mandatory. Routine cultures ventilation to patients without the need for endotracheal
are recommended. Prompt antibiotic therapy should be intubation. There is a strong consensus that one of
given when indicated. these two techniques should be used before
Diabetes: AHF is associated with impaired metabolic endotracheal intubation and mechanical ventilation.
control. Hyperglycaemia occurs commonly. Routine hypo- Utilization of non-invasive techniques dramatically
glycaemic drugs should be stopped and glycaemic control reduce the need for endotracheal intubation and
should be obtained by using short-acting insulin titrated mechanical ventilation.
according to repeated blood glucose measurements.
Normoglycaemia improves survival in diabetic patients
who are critically ill.50 9.2.1. Rationale. Application of CPAP can cause pul-
Catabolic state: negative caloric and nitrogen balance monary recruitment and is associated with an increase
is a problem in ongoing AHF. This is related to reduced in the functional residual capacity. The improved pul-
caloric intake due to reduced intestinal absorption. monary compliance, reduced transdiaphragmatic press-
Care should be undertaken to maintain calorie and ure swings, and decreased diaphragmatic activity can
The use of increased concentrations of oxygen in There are insufcient data to demonstrate a signicant
patients without evidence of hypoxaemia is more contro- reduction in mortality; however, the data do not trend in
versial and may cause harm.63 that direction.
396 ESC Guidelines
9.3. Mechanical ventilation with endotracheal unfractionated heparin (given as 5000 IU twice or thrice
intubation in AHF daily). Careful monitoring of the coagulation system
Invasive mechanical ventilation (with endotracheal intu- is mandatory in AHF as there is often concomitant liver
bation) should not be used to reverse hypoxaemia that dysfunction. LMWH is contraindicated if the creatinine
could be better restored by oxygen therapy, CPAP, or clearance is below 30 mL/min or should be used with
NIPPV, but rather to reverse AHF-induced respiratory extreme care with monitoring of the anti-Factor Xa level.
muscle fatigue. The latter is the most frequent reason
for endotracheal intubation and mechanical ventilation.
10.3. Vasodilators in the treatment of AHF
Respiratory muscle fatigue may be diagnosed by a
Vasodilators are indicated in most patients with acute
decrease in respiratory rate, associated with hypercapnia
heart failure as rst line therapy, if hypoperfusion is
and confused state of mind.
associated with an adequate blood pressure and signs
Invasive mechanical ventilation should only be used if
of congestion with low diuresis, to open the peripheral
acute respiratory failure does not respond to vasodila-
circulation and to lower pre-load (Table 6 ).
tors, oxygen therapy, and/or CPAP, or NIPPV. Another con-
sideration should be the need for immediate intervention
in a patient with pulmonary oedema secondary to 10.3.1. Nitrates. Nitrates relieve pulmonary congestion
ST-elevation acute coronary syndrome. without compromising stroke volume or increasing myo-
cardial oxygen demand in acute left heart failure, par-
10. Medical treatment ticularly in patients with acute coronary syndrome. At
Glyceryl trinitrate, Acute heart failure, Start 20 mg/min, increase Hypotension, Tolerance on
5-mononitrate when blood to 200 mg/min headache continuous use
pressure is adequate
Isosorbide dinitrate Acute heart failure, Start with 1 mg/h, Hypotension, Tolerance on
when blood pressure increase to 10 mg/h headache continuous use
is adequate
Nitroprusside Hypertensive crisis, 0.35mg/kg/min Hypotension, Drug is light sensitive
cardiogenic shock isocyanate toxicity
combined with
intoropes
Nesiritidea Acute decompensated Bolus 2 mg/kg infusion Hypotension
heart failure 0.0150.03 mg/kg/min
a
Limited sales approval in ESC countries.
ESC Guidelines 397
In practical use nitrates have a U-shaped curve effect. enhanced sodium excretion, and suppression of the
If given in sub-optimal doses vasodilators may have a reninangiotensinaldosterone and sympathetic nervous
limited effect in preventing AHF recurrences. However, systems.79 Nesiritide was compared to intravenous nitro-
administration of high doses may also reduce their glycerin and resulted in improvement in haemodynamics
effectiveness. One disadvantage of nitrates is the rapid more effectively and with fewer adverse effects,
development of tolerance especially when given intra- although this did not translate into improvement in clini-
venously in high doses, limiting their effectiveness to cal outcome. Nesiritide may cause hypotension and some
1624 h only. Nitrates should be given at doses aimed patients are non-responders.
at achieving optimal vasodilation, leading to an increase
in cardiac index (CI) and decrease in pulmonary wedge 10.3.4. Calcium antagonists. Calcium antagonists are
pressure. Inappropriate vasodilation may induce a steep not recommended in the treatment of AHF. Diltiazem
reduction in blood pressure, which may result in haemo- and verapamil, and dihydropyridines, should be con-
dynamic instability. sidered contraindicated.
Nitroglycerin can be administered orally or by inhala-
tion [glyceryl trinitrate (GTN) spray 400 mg (2 puffs) 10.4. Angiotensin converting enzyme
every 510 min], or buccally (isosorbide dinitrate 1 or (ACE)-inhibitors in AHF
3 mg), while monitoring blood pressure. The intravenous 10.4.1. Indications. ACE-inhibitors are not indicated
administration and dosing of nitrates (glycerylnitrate in the early stabilization of patients with AHF.
20 mg/min increasing dose to 200 mg/min, or isosorbide Class IIb recommendation, level of evidence C
HCTZ hydrochlorothiazide.
ESC Guidelines 399
The initial oral dose of bisoprolol, carvedilol, or meto- risks of arrhythmias and, in some cases, myocardial
prolol should be small and increased slowly and progress- ischaemia and by the possible long-term progression of
ively to the target dose used in the large clinical trials. myocardial dysfunction caused by an excessive increase
Up-titration should be adapted to individual response. in energy expenditure.114,115 The risk-benet ratio
b-blockers may reduce blood pressure and heart rate may not, however, be the same for all the inotropic
excessively. As a general rule, patients on b-blockers agents. Those acting through the stimulation of the
admitted to hospital due to worsening heart failure b1-adrenergic receptors which increase cytoplasmic
should be continued on this therapy unless inotropic myocardial cell Ca concentration may be associated
support is needed but the dose could be reduced if with the greatest risk.116,117 Lastly, only a few controlled
signs of excessive dosage are suspected (i.e. bradycardia trials with inotropic agents in patients with AHF have
and hypotension). been performed, and very few have assessed their
effects on the symptoms and signs of heart failure and
10.7. Inotropic agents their long-term effects on prognosis.117
10.7.1. Clinical indications. Inotropic agents are
indicated in the presence of peripheral hypoperfusion
(hypotension, decreased renal function) with or without 10.7.2. Dopamine. At low doses (,2 mg/kg/min i.v.)
congestion or pulmonary oedema refractory to diuretics dopamine acts only on peripheral dopaminergic recep-
and vasodilators at optimal doses (Figure 6 ). tors and lowers peripheral resistance both directly and
Class IIa recommendation, level of evidence C indirectly. Vasodilation occurs predominantly in the
renal, splanchnic, coronary, and cerebral vascular beds.
Their use is potentially harmful as they increase oxygen At this dosage, its action may cause an improvement in
demand and calcium loading and they should be used renal blood ow, glomerular ltration rate, diuresis,
with caution.114 and sodium excretion rate, with an increased response
In patients with decompensated CHF the symptoms, to diuretic agents, in patients with renal hypoperfusion
clinical course, and prognosis of the disease may and failure.118121
become critically dependent on the haemodynamics. At higher doses (.2 mg/kg/min i.v.) dopamine stimu-
Thus, improvements in the haemodynamic parameters lates the b-adrenergic receptors both directly and
may become a goal of treatment and inotropic agents indirectly with a consequent increase in myocardial con-
may be useful and life-saving in this setting. The bene- tractility and cardiac output. At doses .5 mg/kg/min
cial effects of an improvement in the haemodynamic dopamine acts on a-adrenergic receptors with an
parameters is, however, partially counteracted by the increase in the peripheral vascular resistance which,
ESC Guidelines 401
though potentially useful in hypotensive patients, may be decreased renal function) with or without congestion or
deleterious in patients with AHF, as it may augment the pulmonary oedema refractory to diuretics and vasodila-
LV after-load, pulmonary artery pressure, and pulmonary tors at optimal doses (Table 11 ).
resistance.122 Class IIa recommendation, level of evidence C
10.7.3. Dobutamine. Dobutamine is a positive inotropic Dobutamine is used to increase the cardiac output. It is
agent acting mainly through stimulation of b1-receptors usually initiated with a 23 mg/kg/min infusion rate
and b2-receptors to produce dose-dependent positive without a loading dose. The infusion rate may then be
inotropic and chronotropic effects,123,124 and a reex progressively modied according to symptoms, diuretic
decrease in sympathetic tone, and thus vascular resis- response, or haemodynamic monitoring. Its haemo-
tance.125 The resultant benet may therefore differ dynamic actions are proportional to its dosage, which
from patient to patient. At low doses, dobutamine can be increased to 20 mg/kg/min. The elimination of
induces mild arterial vasodilatation, which augments the drug is rapid after cessation of infusion, making it a
stroke volume by reductions in after-load. At higher very convenient inotropic agent.
doses dobutamine causes vasoconstriction.77 In patients receiving b-blocker therapy with metopro-
Heart rate is generally increased in a dose-dependent lol, dobutamine doses have to be increased as high as
manner to a lesser extent than with other cathechol- 1520 mg/kg/min to restore its inotropic effect.128 The
amines. However, in patients with atrial brillation, effect of dobutamine differs in patients receiving carve-
heart rate may be increased to undesirable rates, due dilol: it can lead to an increase in pulmonary vascular
strict potassium compensation during intravenous diure- prolonged haemodynamic effects of a 24 h levosimendan
tic use. Tachycardia may also be a limiting parameter, infusion.138,139
and dobutamine infusion may trigger chest pain in Levosimendan is indicated in patients with sympto-
patients with coronary artery disease. In patients with matic low cardiac output heart failure secondary to
hibernating myocardium dobutamine appears to increase cardiac systolic dysfunction without severe hypotension
contractility in the short term at the expense of myocyte (Table 11 ).
necrosis and loss in myocardial recovery.134 There are no Class of recommendation IIa, level of evidence B
controlled trials on dobutamine in AHF patients and some
trials show unfavourable effects with increased untoward Levosimendan is generally administered as a conti-
cardiovascular events.42,116 nuous intravenous infusion at a dose of
0.050.1 mg/kg/min preceded by a loading dose of
1224 mg/kg, administered over 10 min.42,140142 Its
10.7.5. Phosphodiesterase inhibitors. Milrinone and haemodynamic effects are dose-dependent and the infu-
enoximone are the two Type III phosphodiesterase sion rate may be up-titrated to a maximal rate of
inhibitors (PDEIs) used in clinical practice. In AHF, these 0.2 mg/kg/min.165 Most of the clinical data have been
agents have signicant inotropic, lusitropic, and peri- obtained with intravenous infusions lasting from 6 h142 to
pheral vasodilating effects with an increase in cardiac 24 h,42,141 but the haemodynamic effects persist for
output and stroke volume, and a concomitant decline in .48 h after the end of the infusion.138,143
pulmonary artery pressure, pulmonary wedge pressure, Levosimendan infusion in patients with acutely decom-
systemic and pulmonary vascular resistance.122,135 Their
monitoring and monitoring of haemodynamic response by 11. Underlying diseases and co-morbidities
PAC is recommended (Table 11 ). in AHF
Figure 7 Algorithm: AHF in AMI. IABP intra-aortic balloon pump; VSR ventricular septal rupture; PAC pulmonary artery catheterization; TEE
trans-esophageal echocardiography; EF ejection fraction; MR mitral regurgitation; IVS intraventricular septum; SAM systolic anterior movement;
RA right atrium; RV right ventricle; PCI percutaneous coronary intervention; Qp:Qs pulmonary circulation volume:systemic circulation volume.
ESC Guidelines 405
pulmonary oedema. Inotropic agents may be deleterious. structural defects of the prosthetic valve should be
Intra-aortic balloon counter-pulsation (IABC) should be ruled out by transoesophageal echocardiography.168
considered.155,157,158 Echocardiography should be performed in all patients
The long-term management strategy should include after thrombolytic therapy. Surgical intervention should
adequate coronary revascularization and, where there be considered in all cases if thrombolysis fails to
is evidence of reduced LV function, long-term treat- resolve the obstruction although repeated infusions of
ment with renin angiotensin aldosterone system thrombolytic therapy are an alternative.166,169
(RAAS)-inhibition and b-blockade should follow. The thrombolytics used are: rtPA 10-mg iv bolus fol-
Acute right heart failure is usually related to acute lowed by 90 mg infused over 90 min; streptokinase
RV ischaemia in acute coronary syndromes, particularly 2505 00 000 IU over 20 min followed by 11.5 million
RV infarction with a characteristic electro- and IU infused over 10 h. After thrombolysis, unfractionated
echo-cardiogram. Early revascularization of the right heparin should be administered by intravenous infusion
coronary artery and its ventricular branches is rec- in all patients (activated partial thromboplastin time
ommended. Supportive treatment should focus on 1.52.0 times control). Urokinase is also an alternative
uid-loading and inotropic support. in a dose of 4400 IU/kg/h without heparin for 12 h or
2000 IU/kg/h with heparin for 24 h.
11.2. Valvular disease
AHF can be caused by valvular conditions unrelated 11.4. Aortic dissection
to acute coronary syndromes, such as acute mitral or Acute aortic dissection (particularly Type 1) may present
medications given alone, or combined, if hypertension predictor of mortality in heart failure patients.102 In
persists: (i) intravenous loop diuretics, particularly if such patients, it may be necessary to progressively
the patient is clearly uid overloaded with a long increase the dose of the loop diuretics and/or add a
history of CHF; (ii) intravenous nitroglycerin or nitroprus- diuretic with a different mechanism of action (e.g.
side to decrease venous pre-load and arterial after-load, metozalone). This may, however, be associated with
and increase coronary blood ow; (iii) a calcium-channel hypokalaemia and a further decline in GFR.
blocker (such as nicardipine) may be considered as these In patients with severe renal dysfunction and
patients usually have diastolic dysfunction with an refractory uid retention, continuous veno-venous
increased after-load. haemoltration (CVVH) may become necessary. Com-
b-blockers should not be advised in cases of concomi- bined with a positive inotropic agent this may increase
tant pulmonary oedema. However, in some cases, and renal blood blow, improve renal function, and restore
particularly in hypertensive crisis related to phaeo- diuretic efciency. This has been associated with an
chromocytoma, intravenous labetalol, given as slow increase in urine output, a reduction in symptoms, in
boluses of 10 mg whilst monitoring heart rate and blood left and right ventricular lling pressures, and symp-
pressure, and followed by an infusion of 50200 mg/h, athetic stimulation, and with an improvement in lung
can be effective. mechanical function, laboratory abnormalities (hypona-
traemia), and response to diuretic therapy.180 Loss of
renal function may require dialysis treatment especially
11.6. Renal failure in the presence of hyponatraemia, acidosis, and overt
Ventricular brillation or Debrillate with 200300360J (preferably by biphasic debrillation with a maximum of
pulseless ventricular tachycardia 200J). If refractory to initial shocks inject epinephrine 1 mg or vasopressin 40 IU and/or
amiodarone 150300 mg as injection
Ventricular tachycardia If patient is unstable cardiovert, if stable amiodarone or lidocaine can be given to achieve
medical cardioversion.
Sinus tachycardia or Use b-blocking agents when clinically and haemodynamically tolerated:
supraventricular tachycardia Metoprolol 5 mg intravenously as a slow bolus (can be repeated if tolerated)
Adenosine may be used to slow AV conduction or to cardiovert re-entrant tachycardia
On rare occasions:
Esmolol 0.51.0 mg/kg over 1 min, followed by infusion of 50300 mg/kg/min, or
Labetalol 12 mg bolus, followed by infusion of 12 mg/min (to total of 50200 mg).
Labetalol also indicated in AHF related to hypertensive crisis or phaeochoromcytoma,
with 10-mg boluses, to a total dose of 300 mg.
Atrial brillation or utter Cardiovert if possible. Digoxin 0.1250.25 mg iv, or b-blocking agent, or amiodarone, may
be used to slow AV conduction. Amiodarone may induce medical cardioversion without
compromising left ventricular haemodynamics. Patient should be heparinized.
Bradycardia Atropine 0.250.5 mg iv, to total of 12 mg.
As interim measure, isoproterenol 1 mg in 100 mL NaCl infused to a maximum of 75mL/h
(212mg/min).
population they were found as a concomitant early or rate reduction. Rapid rate control or cardioversion on
acute problem in 8% of patients.5 clinical demand should be achieved (Table 12 ). The
therapy of AF depends on its duration.31
11.8.1. Bradyarrhythmias. Bradycardia in AHF patients Patients with AHF and AF should be anticoagulated.
occurs most often in AMI, particularly with right coronary When AF is paroxysmal, medical or electrical cardioversion
artery occlusion. should be considered after initial work-up and stabilization
The treatment of bradyarrhythmias is usually initially of the patient. If the duration of the AF is more than 48 h
with atropine 0.250.5 mg iv, repeated when needed. the patient should be anticoagulated and optimal rate
Isoproterenol 220 mg/min can be infused in cases of AV control achieved medically for 3 weeks before cardiover-
dissociation with low ventricular response, but should sion. If the patient is haemodynamically unstable, urgent
be avoided in ischaemic conditions. Slow ventricular cardioversion is clinically mandatory, but atrial thrombus
rhythm in atrial brillation can be improved by iv theo- should be excluded by transoesophageal echocardiography
phylline 0.20.4 mg/kg/h as a bolus and then by infusion. prior to cardioversion.31
A temporary pacemaker should be inserted if no response Verapamil and diltiazem should be avoided in acute AF
is achieved with medical therapy.187 Ischaemia should as they may worsen heart failure and cause third degree
be treated as soon as possible before or after inserting AV block. Amiodarone and b-blocking agents have been
a pacemaker as indicated188190 (Table 12 ). successfully used in AF for rate control and prevention of
Class IIa recommendation, level of evidence C recurrence.3,192
Class I recommendation, level of evidence A
11.8.2. Supraventricular tachycardia (SVT). Supraven- Verapamil can be considered in the treatment of AF
tricular tachyarrhythmias may complicate or cause or narrow complex SVT in patients with only slightly
AHF.191 On rare occasions persistent atrial tachycardias reduced ventricular systolic function.
may cause decompensated heart failure requiring Class I anti-arrhythmic agents should be avoided in
hospitalization. Similarly, atrial brillation with a rapid patients with low ejection fraction and particularly in
ventricular response may be the cause for a dilated patients who have a wide QRS complex. Dofetilide is a
cardiomyopathy and AHF. new drug with promising results in medical cardioversion
and prevention of new AF, but further studies are needed
11.8.3. Recommendations for treatment of supraven- to evaluate its safety and efcacy in AHF.193
tricular tachyarrhythmias in AHF. The control of the b-blocking agents can be tried in SVTs when
ventricular rate response is important in patients with tolerated.194,195 In wide complex tachycardia, intrave-
AF and AHF, particularly in patients with diastolic dys- nous adenosine can be used in an attempt to terminate
function.31 the arrhythmia. Electrical cardioversion of SVT with
Class IIa recommendation, level of evidence A sedation should be considered in AHF with hypotension.
AHF patients with AMI and heart failure, and patients
Patients with restrictive physiology or tamponade, with diastolic heart failure, do not tolerate rapid supra-
however, may suddenly deteriorate with rapid heart ventricular arrhythmias.
408 ESC Guidelines
patients. Hospital mortality is 2060% in patients under- 13. Mechanical assist devices and
going surgical repair. Improvements in surgical technique heart transplantation
and myocardial protection improved outcome in recent
series.173,202 13.1. Indication
There is a developing consensus that surgery should be Temporary mechanical circulatory assistance may be
performed as soon as the diagnosis is made, because the indicated in patients with AHF who are not responding
rupture can abruptly expand resulting in cardiogenic to conventional therapy and where there is the potential
shock, the most important determinant of adverse for myocardial recovery, or as a bridge to heart trans-
outcome.174,203 The patients with VSR should be operated plant or interventions that may result in signicant
on urgently if they are in haemodynamically stable recovery of the heart function (Figure 8 ).
condition and immediately if they are in cardiogenic Class IIb recommendation, level of evidence B
shock.
Class I recommendation, level of evidence C Improvement in the design and function of the devices
will increase the number of potential candidates for its
Recently, left ventricular outow tract (LVOT) obstruc- short and long-term use in the future.
tion with compensatory hyperkinesis of the basal seg-
ments of the heart has been described in some patients 13.1.1. Intra-aortic balloon counterpulsation (IABC).
with apical anterior myocardial infarction as a cause Counter-pulsation has become a standard component of
of a new systolic murmur and cardiogenic shock. It treatment in patients with cardiogenic shock or severe
system. In some patients the haemodynamic and clinical institutional programme. Table 14 summarizes the more
improvement may be spectacular. frequently used systems and the main indications.
If recovery from AHF or transplantation is not possible Class IIa recommendation, level of evidence B
then the use of ventricular assist devices is unacceptable.
The treatment of patients with LV assist devices vs. con- Thromboembolism, bleeding, and infection are the
ventional treatment in a randomized clinical trial impro- most common complications associated with the use of
ved the prognosis of end-stage heart failure patients ventricular assist devices.208210 Haemolysis and device
compared with conventional care, but was expensive malfunction are also frequent.
and accompanied by frequent infections and thrombotic
complications.212 Experience is needed for the implan- 13.2. Heart transplantation
tation and service of the pump and these devices Transplantation can be considered as a possibility in
should only be used within the framework of an severe AHF known to have a poor outcome. This is the
ESC Guidelines 411
Extracorporeal
Continuous ow pumps Several Short term support Easiest to use. Cheapest
Centrifugal pumps Several Extensive experience
May include extracorporeal membrane
oxygenators
Need for continuous monitoring
Patient bedridden
Pulsatile Thoratec Short term support Easy to use. Not expensive
Abiomed Post cardiotomy Need for continuous monitoring
LV and RV dysfunction Patient bedridden
Bridge to heart transplant
Intracorporeal
Implantable, pulsatiles Heart Mate Long term use possible Expensive
Novacor Bridge to transplant Patient may move and rehabilitate
Bridge to recovery
Total articial heart No recovery expected Experimental
No transplant candidate Limited experience
case in severe acute myocarditis or in post-puerperal . Diuretic therapy by furosemide or other loop diuretic
cardiomyopathy or in a patient with major myocardial (initially intravenous bolus followed by continuous
infarction with an initially poor outcome after revascu- intravenous infusion, when needed)
larization. However, transplantation is not possible until . Morphine for relief of physical and psychological dis-
the patients condition has been stabilized with the aid tress and to improve haemodynamics
of devices and articial pumps. . Intravenous uids should be given if the clinical con-
dition is pre-load-dependent and there are signs of
low lling pressure. This may require testing the
14. Summary comments response to an aliquot of uid.
. Other complicating metabolic and organ-specic con-
The clinical syndrome of AHF may present as de novo AHF ditions should be treated on their own merits.
or as decompensated CHF with forward, left (backward), . Patients with acute coronary syndrome or other com-
or right (backward) dominance in the clinical syndrome. plicated cardiac disorders should undergo cardiac
A patient with AHF requires immediate diagnostic catheterization and angiography, with a view to inva-
evaluation and care, and frequent resuscitative measures sive intervention including surgery.
to improve symptoms and survival. . Appropriate medical treatment by b-blocking agents
Initial diagnostic assessment should include clinical and other medical therapy should be initiated as
examination supported by the patients history, ECG, described in this report.
chest X-ray, plasma BNP/NT-proBNP, and other laboratory
tests. Echocardiography should be performed in all
Further specic therapies (Figures 5, 6, 7 and Table 14 )
patients as soon as possible (unless recently done and
should be administered based on the clinical and haemo-
the result is available).
dynamic characteristics of the patient who does not
The initial clinical assessment should include evalua-
respond to initial treatment. This may include the use
tion of pre-load, after-load, and the presence of mitral
of inotropic agents or a calcium sensitizer for severe
regurgitation (MR) and other complicating disorders
decompensated heart failure, or inotropic agents for car-
(including valvular complications, arrhythmia, and con-
diogenic shock.
comitant co-morbidities such as infection, diabetes mel-
The aim of therapy of AHF is to correct hypoxia and
litus, respiratory, or renal diseases). Acute coronary
increase cardiac output, renal perfusion, sodium excre-
syndromes are a frequent cause of AHF and coronary
tion, and urine output. Other therapies may be required
angiography is often required.
e.g. intravenous aminophylline or b2-agonist for bronch-
Following initial assessment, an intravenous line should
odilation. Ultraltration or dialysis may be prescribed
be inserted, and physical signs, ECG and SPO2 should be
for refractory heart failure.
monitored. An arterial line should be inserted when
Patients with refractory AHF or end-stage heart failure
needed.
should be considered for further support, where indi-
The initial treatment of AHF consists of:
cated (Figures 7 and 8 ) including: intra-aortic balloon
. Oxygenation with face-mask or by CPAP (SPO2 target of pump, articial mechanical ventilation, or circulatory
9496%) assist devices as a temporary measure, or as a bridge
. Vasodilatation by nitrate or nitroprusside to heart transplantation.
412 ESC Guidelines
The patient with AHF may recover extremely well, cardiovascular nursing council of the American Heart Association.
depending on the aetiology and the underlying pathophy- Circulation 2000;1002:24432456.
22. Nohria A, Lewis E, Stevenson LW. Medical management of advanced
siology. Prolonged treatment on the ward and expert care heart failure. JAMA 2002;287:628640.
are required. This is best delivered by a specialist heart 23. Killip T, 3rd, Kimball JT. Treatment of myocardial infarction in a
failure team that can rapidly initiate medical manage- coronary care unit. A two year experience with 250 patients. Am J
ment and attend to the information needs of the Cardiol 1967;20:457464.
24. Forrester JS, Diamond GA, Swan HJ. Correlative classication of
patient and family.
clinical and hemodynamic function after acute myocardial infarc-
tion. Am J Cardiol 1977;39:137145.
25. Arnold JM, Braunwald E, Sandor T et al. Inotropic stimulation of
References reperfused myocardium with dopamine: effects on infarct size and
myocardial function. J Am Coll Cardiol 1985;6:10261034.
26. Bolli R. Basic and clinical aspects of myocardial stunning. Prog Car-
1. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment
diovasc Dis 1998;40:477516.
of chronic heart failure. Eur Heart J 2001;22:15271560.
27. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J
2. Guidelines on the diagnosis and treatment of acute heart failure.
Med 1998;339:173181.
Available at http://www.escardio.org.
3. Effect of prophylactic amiodarone on mortality after acute myocar- 28. Marban E. Myocardial stunning and hibernation. The physiology
dial infarction and in congestive heart failure: meta-analysis of indi- behind the colloquialisms. Circulation 1991;83:681688.
vidual data from 6500 patients in randomised trials. Amiodarone 29. Bertrand ME, Simoons ML, Fox KA et al. Management of acute coron-
Trials Meta-Analysis Investigators. Lancet 1997;350:14171424. ary syndromes in patients presenting without persistent ST-segment
4. McCullough PA, Philbin EF, Spertus JA et al. Conrmation of a heart elevation. Eur Heart J 2002;23:18091840.
failure epidemic: ndings from the Resource Utilization Among 30. Van de Werf F, Ardissino D, Betriu A et al. Management of acute myo-
42. Follath F, Cleland JG, Just H et al. Efcacy and safety of intravenous 65. Bersten AD, Holt AW, Vedig AE et al. Treatment of severe cardio-
levosimendan compared with dobutamine in severe low-output genic pulmonary edema with continuous positive airway pressure
heart failure (the LIDO study): a randomised double-blind trial. delivered by face mask. N Engl J Med 1991;325:18251830.
Lancet 2002;360:196202. 66. Lin M, Yang YF, Chiang HT et al. Reappraisal of continuous positive
43. Steimle AE, Stevenson LW, Chelimsky-Fallick C et al. Sustained airway pressure therapy in acute cardiogenic pulmonary edema.
hemodynamic efcacy of therapy tailored to reduce lling pressures Short-term results and long-term follow-up. Chest
in survivors with advanced heart failure. Circulation 1995;107:13791386.
1997;96:11651172. 67. Takeda S, Nejima J, Takano T et al. Effect of nasal continuous posi-
44. Gottlieb SS, Brater DC, Thomas I et al. BG9719 (CVT-124), an A1 ade- tive airway pressure on pulmonary edema complicating acute myo-
nosine receptor antagonist, protects against the decline in renal cardial infarction. Jpn Circ J 1998;62:553558.
function observed with diuretic therapy. Circulation 68. Kelly CA, Newby DE, McDonagh TA et al. Randomised controlled trial
2002;105:13481353. of continuous positive airway pressure and standard oxygen therapy
45. Shah MR, Stinnett SS, McNulty SE et al. Hemodynamics as surrogate in acute pulmonary oedema; effects on plasma brain natriuretic
end points for survival in advanced heart failure: an analysis from peptide concentrations. Eur Heart J 2002;23:13791386.
FIRST. Am Heart J 2001;141:908914.
69. Pang D, Keenan SP, Cook DJ et al. The effect of positive pressure
46. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the
airway support on mortality and the need for intubation in
effect of deliberate perioperative increase of oxygen delivery on
cardiogenic pulmonary edema: a systematic review. Chest
mortality in high-risk surgical patients. JAMA 1993;270:26992707.
1998;114:11851192.
47. Sandham JD, Hull RD, Brant RF et al. A randomized, controlled trial
70. Masip J, Betbese AJ, Paez J et al. Non-invasive pressure support ven-
of the use of pulmonary-artery catheters in high-risk surgical
tilation versus conventional oxygen therapy in acute cardiogenic
patients. N Engl J Med 2003;348:514.
pulmonary oedema: a randomised trial. Lancet 2000;356:
48. Rhodes A, Cusack RJ, Newman PJ et al. A randomised, controlled
21262132.
trial of the pulmonary artery catheter in critically ill patients.
86. Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly 111. Herlitz J, Elmfeldt D, Hjalmarson A et al. Effect of metoprolol on
decreases after intravenous therapy with diuretics and vasodilators indirect signs of the size and severity of acute myocardial infarction.
for class IV heart failure. J Am Coll Cardiol 2002;39:16231629. Am J Cardiol 1983;51:12821288.
87. Brater DC. Resistance to loop diuretics. Why it happens and what to 112. Witchitz S, Cohen-Solal A, Dartois N et al. Treatment of heart failure
do about it. Drugs 1985;30:427443. with celiprolol, a cardioselective beta blocker with beta-2 agonist
88. Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose vasodilatory properties. The CELICARD Group. Am J Cardiol
isosorbide dinitrate plus low-dose furosemide versus high-dose furo- 2000;85:14671471.
semide plus low-dose isosorbide dinitrate in severe pulmonary 113. Held PH, Corbeij HM, Dunselman P et al. Hemodynamic effects of
oedema [see comments]. Lancet 1998;351:389393. metoprolol in acute myocardial infarction. A randomized, placebo-
89. Gardtman M, Waagstein L, Karlsson T et al. Has an intensied treat- controlled multicenter study. Am J Cardiol 1985;56:47G54G.
ment in the ambulance of patients with acute severe left heart 114. Katz AM. Potential deleterious effects of inotropic agents in the
failure improved the outcome? Eur J Emerg Med 2000;7:1524. therapy of chronic heart failure. Circulation 1986;73:III184III90.
90. Sacchetti A, Ramoska E, Moakes ME et al. Effect of ED management 115. Packer M. The development of positive inotropic agents for chronic
on ICU use in acute pulmonary edema. Am J Emerg Med heart failure: how have we gone astray? J Am Coll Cardiol
1999;17:571574. 1993;22:119A126A.
91. Kramer WG, Smith WB, Ferguson J et al. Pharmacodynamics of tor- 116. OConnor CM, Gattis WA, Uretsky BF et al. Continuous intravenous
semide administered as an intravenous injection and as a continuous dobutamine is associated with an increased risk of death in patients
infusion to patients with congestive heart failure. J Clin Pharmacol with advanced heart failure: Insights from the Flolan International
1996;36:265270. Randomized Survival Trial (FIRST). Am Heart J 1999;138:7886.
92. Lahav M, Regev A, Raanani P et al. Intermittent administration of 117. Thackray S, Easthaugh J, Freemantle N et al. The effectiveness and
furosemide vs continuous infusion preceded by a loading dose for relative effectiveness of intravenous inotropic drugs acting through
congestive heart failure. Chest 1992;102:725731. the adrenergic pathway in patients with heart failurea meta-
93. Pivac N, Rumboldt Z, Sardelic S et al. Diuretic effects of furosemide
132. Caldicott LD, Hawley K, Heppell R et al. Intravenous enoximone or 155. Wong SC, Sanborn T, Sleeper LA et al. Angiographic ndings and
dobutamine for severe heart failure after acute myocardial infarc- clinical correlates in patients with cardiogenic shock complicating
tion: a randomized double-blind trial. Eur Heart J 1993;14:696700. acute myocardial infarction: a report from the SHOCK Trial Registry.
133. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type SHould we emergently revascularize Occluded Coronaries for car-
natriuretic peptide) and dobutamine on ventricular arrhythmias in diogenic shocK? J Am Coll Cardiol 2000;36:10771083.
the treatment of patients with acutely decompensated congestive 156. Malmberg K, Norhammar A, Wedel H et al. Glycometabolic state at
heart failure: the PRECEDENT study. Am Heart J 2002;144: admission: important risk marker of mortality in conventionally
11021108. treated patients with diabetes mellitus and acute myocardial infarc-
134. Schulz R, Rose J, Martin C et al. Development of short-term myocar- tion: long-term results from the Diabetes and Insulin-Glucose Infu-
dial hibernation. Its limitation by the severity of ischemia and ino- sion in Acute Myocardial Infarction (DIGAMI) study. Circulation
tropic stimulation. Circulation 1993;88:684695. 1999;99:26262632.
135. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in 157. Hochman JS, Buller CE, Sleeper LA et al. Cardiogenic shock compli-
the treatment of congestive heart failure. Mechanisms of action and cating acute myocardial infarctionetiologies, management and
recent clinical developments. 2. N Engl J Med 1986;314:349358. outcome: a report from the SHOCK Trial Registry. Should we emer-
136. Bohm M, Deutsch HJ, Hartmann D et al. Improvement of postrecep- gently revascularize occluded Coronaries for cardiogenic shock? J
tor events by metoprolol treatment in patients with chronic heart Am Coll Cardiol 2000;36:10631070.
failure. J Am Coll Cardiol 1997;30:992996. 158. Menon V, Slater JN, White HD et al. Acute myocardial infarction
137. Loh E, Elkayam U, Cody R et al. A randomized multicenter study complicated by systemic hypoperfusion without hypotension:
comparing the efcacy and safety of intravenous milrinone and report of the SHOCK trial registry. Am J Med 2000;108:374380.
intravenous nitroglycerin in patients with advanced heart failure. 159. Sexton DJ, Spelman D. Current best practices and guidelines. Assess-
J Card Fail 2001;7:114121. ment and management of complications in infective endocarditis.
138. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects Cardiol Clin 2003;21:273282.
of intravenous levosimendan. Circulation 2003;107:8186. 160. Olaison L, Pettersson G. Current best practices and guidelines. Indi-
176. Anand IS, Chugh SS. Mechanisms and management of renal dysfunc- lines for the Management of Patients with Supraventricular
tion in heart failure. Curr Opin Cardiol 1997;12:251258. Arrhythmias) developed in collaboration with NASPE-Heart Rhythm
177. Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunc- Society. J Am Coll Cardiol 2003;42:14931531.
tion during intensive therapy for advanced chronic heart failure. Am 195. Hebbar AK, Hueston WJ. Management of common arrhythmias: Part
Heart J 1999;138:285290. I. Supraventricular arrhythmias. Am Fam Physician 2002;65:
178. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohor- 24792486.
monal activation, and survival in patients with chronic heart 196. The pre-hospital management of acute heart attacks. Recommen-
failure. Circulation 2000;102:203210. dations of a Task Force of the The European Society of Cardiology
179. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of and The European Resuscitation Council. Eur Heart J
the major electrolyte abnormalities in congestive heart failure: 1998;19:11401164.
hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 197. Ellison KE, Stevenson WG, Sweeney MO et al. Catheter ablation for
1994;128:564574. hemodynamically unstable monomorphic ventricular tachycardia. J
180. Agostoni PG, Marenzi GC, Sganzerla P et al. Lung-heart interaction Cardiovasc Electrophysiol 2000;11:4144.
as a substrate for the improvement in exercise capacity after body 198. Pohjola-Sintonen S, Muller JE, Stone PH et al. Ventricular septal and
uid volume depletion in moderate congestive heart failure. Am J free wall rupture complicating acute myocardial infarction: experi-
Cardiol 1995;76:793798. ence in the Multicenter Investigation of Limitation of Infarct Size.
181. Sharma A, Hermann DD, Mehta RL. Clinical benet and approach of Am Heart J 1989;117:809818.
ultraltration in acute heart failure. Cardiology 2001;96:144154. 199. London RE LS. The electrocardiographic signs of acute hemopericar-
182. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radio- dium. Circulation 1962;25:780786.
graphic-contrast-agent-induced reductions in renal function by 200. Lopez-Sendon J, Gonzalez A, Lopez de Sa E et al. Diagnosis of sub-
acetylcysteine. N Engl J Med 2000;343:180184. acute ventricular wall rupture after acute myocardial infarction:
183. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and con- sensitivity and specicity of clinical, hemodynamic and echocardio-
trast agent-associated nephrotoxicity. J Am Coll Cardiol graphic criteria. J Am Coll Cardiol 1992;19:11451153.